At the same time, the patient dropout rate of the MiniCHAMP trial was less than %, and the subjects' medication compliance was as high as over %. These data not only fully demonstrate the rigor and reliability of clinical research, but also further highlight the advantages of NVK in clinical applications and demonstrate its excellent clinical quality.
This means that Zhaoke’s review in China does not require clinical trial data from its U. partners and is independent of the FDA’s review procedures, thus ensuring the independence and flexibility of its listing plan in China.
In addition to the clinical trials used for registration review, Zhaoke latvia phone number list Ophthalmology also conducted a twoyear Phase III China CHAMP clinical trial in China and completed the last visit of the last patient in August . The positive topline results from the trial demonstrated the remarkable safety and efficacy of NVK, providing further data support for its potential treatment for controlling myopia progression in children.
Overall, the successful breakthrough of NVK is not accidental, but a comprehensive reflection of its advantages in R&D, clinical trials and market strategies. As the second atropine product to formally enter the review process in China, this progress of NVK not only consolidates its leading position in the domestic market, but also further increases the certainty of its successful launch. This not only brings confidence to investors, but also provides strong support for the company's competitiveness in the market.